MCID: CRN017
MIFTS: 46

Coronary Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Coronary Thrombosis

MalaCards integrated aliases for Coronary Thrombosis:

Name: Coronary Thrombosis 12 54 44 15 17 71
Coronary Artery Thrombosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11847
MeSH 44 D003328
SNOMED-CT 67 66514008
ICD10 32 I22
UMLS 71 C0010072

Summaries for Coronary Thrombosis

MalaCards based summary : Coronary Thrombosis, also known as coronary artery thrombosis, is related to angina pectoris and heparin-induced thrombocytopenia. An important gene associated with Coronary Thrombosis is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Cilostazol and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and neutrophil, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 74 Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This... more...

Related Diseases for Coronary Thrombosis

Diseases related to Coronary Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 angina pectoris 30.6 PLAT F3 CRP
2 heparin-induced thrombocytopenia 30.5 SERPINC1 F3
3 inferior myocardial infarction 30.2 PLG PLAT
4 aspirin resistance 30.2 PTGS2 ITGB3
5 catastrophic antiphospholipid syndrome 30.2 SERPINE1 F3
6 protein s deficiency 30.1 SERPINC1 FGA F3
7 factor viii deficiency 30.0 VWF SERPINC1 F3
8 ischemia 29.9 SELP PLG PLAT GP1BA
9 cardiac rupture 29.9 PLAT CRP
10 coronary stenosis 29.9 VWF SERPINE1 CRP
11 hemophilia b 29.7 VWF SERPINC1 FGA F3
12 coronary aneurysm 29.7 PLG CRP
13 splenic infarction 29.7 SERPINC1 F3 CRP
14 acute anterolateral myocardial infarction 29.7 PLG ITGA2B
15 antithrombin iii deficiency 29.7 SERPINC1 PLG FGA
16 heart aneurysm 29.7 PLG CRP
17 endocarditis 29.6 SERPINE1 SERPINC1 PLAT GP1BA CRP
18 toxic shock syndrome 29.6 SERPINC1 F3 CRP
19 homocysteinemia 29.6 VWF SERPINE1 SERPINC1 CRP
20 infective endocarditis 29.6 SERPINE1 ITGB3 GP1BA CRP
21 arteries, anomalies of 29.5 SERPINE1 PLG F3 CRP
22 nonbacterial thrombotic endocarditis 29.4 SERPINC1 PLG F3 CRP
23 atrial heart septal defect 29.4 SERPINC1 PLG F3 CRP
24 atherosclerosis susceptibility 29.3 VWF SERPINE1 SELP F3 CRP
25 thrombophilia due to thrombin defect 29.3 VWF SERPINE1 SERPINC1 PLAT FGA F3
26 cardiac tamponade 29.2 PLG PLAT F3 CRP
27 atrial fibrillation 29.2 VWF SELP PLAT CRP
28 pulmonary embolism 29.2 VWF SERPINE1 SERPINC1 PLAT GP6 GP1BA
29 thrombocytosis 29.1 VWF SERPINC1 SELP FGA F3 CRP
30 thrombocytopenic purpura, autoimmune 29.0 SELP ITGB3 ITGA2B GP6 GP1BA
31 purpura 28.9 VWF SERPINC1 ITGB3 ITGA2B GP1BA F3
32 portal vein thrombosis 28.9 SERPINE1 SERPINC1 SELP PLAT CRP
33 antiphospholipid syndrome 28.8 VWF SERPINE1 SERPINC1 SELP PLAT F3
34 von willebrand's disease 28.8 VWF SELP PLAT ITGA2B GP1BA F3
35 thrombotic thrombocytopenic purpura 28.7 VWF SERPINC1 SELP PLAT ITGB3 F3
36 thrombophilia 28.7 VWF SERPINE1 SERPINC1 SELP PLAT ITGB3
37 thrombosis 28.7 VWF SERPINE1 SERPINC1 SELP PLG PLAT
38 intermediate coronary syndrome 28.4 VWF SERPINC1 SELP PLG PLAT P2RY12
39 thrombophlebitis 28.4 VWF SERPINE1 SERPINC1 PLG PLAT F3
40 arteriosclerosis 28.3 SERPINE1 SERPINC1 SELP ITGB3 ITGA2B GP1BA
41 intracranial embolism 28.2 VWF SERPINC1 SELP PLG PLAT F3
42 acute myocardial infarction 28.2 VWF SERPINE1 SERPINC1 SELP PLG PLAT
43 disseminated intravascular coagulation 28.1 VWF SERPINE1 SERPINC1 PLG PLAT FGA
44 essential thrombocythemia 28.0 VWF SERPINE1 SERPINC1 SELP ITGB3 ITGA2B
45 carotid artery thrombosis 27.6 VWF SERPINE1 SERPINC1 SELP PLG PLAT
46 intracranial thrombosis 27.4 VWF SERPINC1 SELP PLG PLAT ITGA2B
47 lipoprotein quantitative trait locus 27.2 VWF SERPINE1 SELP PLG PLAT P2RY12
48 myocardial infarction 26.9 VWF SLC6A4 SERPINE1 SERPINC1 SELP PTGS2
49 diabetes mellitus 26.9 VWF SERPINE1 SERPINC1 SELP PTGS2 PLAT
50 hypertension, essential 26.7 VWF SLC6A4 SERPINE1 SERPINC1 SELP PTGS2

Graphical network of the top 20 diseases related to Coronary Thrombosis:



Diseases related to Coronary Thrombosis

Symptoms & Phenotypes for Coronary Thrombosis

MGI Mouse Phenotypes related to Coronary Thrombosis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 CRP F3 FGA GP1BA GP6 ITGA2B
2 cardiovascular system MP:0005385 10.41 CRP F3 FGA ITGA2B ITGB3 PLAT
3 hematopoietic system MP:0005397 10.37 F3 FGA GP1BA GP6 ITGA2B ITGB3
4 cellular MP:0005384 10.34 F3 FGA GP1BA ITGA2B ITGB3 PLAT
5 immune system MP:0005387 10.3 CRP F3 FGA GP6 ITGA2B ITGB3
6 integument MP:0010771 10.21 F3 FGA GP6 ITGA2B ITGB3 PLAT
7 mortality/aging MP:0010768 10.21 F3 FGA GP6 ITGA2B ITGB3 PLAT
8 digestive/alimentary MP:0005381 10.16 FGA ITGA2B ITGB3 PLAT PLG PTGS2
9 nervous system MP:0003631 10.1 F3 FGA ITGA2B ITGB3 PLAT PLG
10 liver/biliary system MP:0005370 9.95 FGA ITGB3 PLG PTGS2 SELP SERPINC1
11 reproductive system MP:0005389 9.91 FGA GP6 ITGA2B ITGB3 PLAT PLG
12 respiratory system MP:0005388 9.7 F3 ITGB3 PLAT PLG PTGS2 SELP
13 skeleton MP:0005390 9.61 FGA GP6 ITGA2B ITGB3 PLAT PTGS2
14 vision/eye MP:0005391 9.32 F3 FGA GP6 ITGB3 PLAT PLG

Drugs & Therapeutics for Coronary Thrombosis

Drugs for Coronary Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
3 Anti-Inflammatory Agents Phase 4
4 Analgesics, Non-Narcotic Phase 4
5 Fibrinolytic Agents Phase 4
6 Anti-Inflammatory Agents, Non-Steroidal Phase 4
7 Analgesics Phase 4
8 Antirheumatic Agents Phase 4
9 Cyclooxygenase Inhibitors Phase 4
10 Antipyretics Phase 4
11 Protective Agents Phase 4
12 Respiratory System Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Phosphodiesterase Inhibitors Phase 4
15 Phosphodiesterase 3 Inhibitors Phase 4
16 Neuroprotective Agents Phase 4
17 Bronchodilator Agents Phase 4
18 Vasodilator Agents Phase 4
19 Platelet Aggregation Inhibitors Phase 4
20 Immunosuppressive Agents Phase 4
21 Immunologic Factors Phase 4
22
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
23
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
24 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid Phase 3
25 Neurotransmitter Agents Phase 3
26 Purinergic P2Y Receptor Antagonists Phase 3
27
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
28 Immunoglobulins Phase 1, Phase 2
29 Antibodies Phase 1, Phase 2
30
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
31
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
32
Clotrimazole Approved, Vet_approved 23593-75-1 2812
33
Thrombin Approved, Investigational
34 Chlorhexidine gluconate
35 Antifungal Agents
36 Antibiotics, Antitubercular

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
2 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
3 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Completed NCT00963781 Phase 4 Reduced duration (6 months) DAPT
4 Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
5 A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study). Suspended NCT00353067 Phase 3 veliflapon (DG-031)
6 A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Terminated NCT00557921 Phase 3 CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;Plavix (clopidogrel 75 mg) and aspirin
7 Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study Completed NCT01274234 Phase 1, Phase 2
8 Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals Unknown status NCT00973375
9 Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 Unknown status NCT02591264
10 Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy Unknown status NCT00327041
11 Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry Completed NCT03180931
12 A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic Completed NCT00714623
13 Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department Completed NCT00657436
14 Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease. Completed NCT03034148
15 Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion Completed NCT03342521
16 EKG Criteria and Identification of Acute Coronary Occlusion Recruiting NCT03863327

Search NIH Clinical Center for Coronary Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Tenecteplase
Urokinase

Cochrane evidence based reviews: coronary thrombosis

Genetic Tests for Coronary Thrombosis

Anatomical Context for Coronary Thrombosis

MalaCards organs/tissues related to Coronary Thrombosis:

40
Heart, Endothelial, Neutrophil, Smooth Muscle, Kidney, Lung, Myeloid

Publications for Coronary Thrombosis

Articles related to Coronary Thrombosis:

(show top 50) (show all 2376)
# Title Authors PMID Year
1
[Annexin A5 inhibits homocysteine-induced tissue factor expression and activity in vascular smooth muscle cells]. 54 61
20137335 2009
2
Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation. 54 61
17249334 2007
3
Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. 54 61
16528008 2006
4
Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. 61 54
16377278 2006
5
[Regulatory effect of IL-10 on expression of tissue factor induced by IL-6 in peripheral blood mononuclear cells]. 61 54
15972146 2005
6
Angiographic demonstration of coronary dethrombosis with eptifibatide. 61 54
15156011 2004
7
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 61 54
14963043 2004
8
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. 61 54
12808446 2003
9
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. 54 61
12644882 2003
10
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. 54 61
11028489 2000
11
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. 61 54
10928474 2000
12
Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Témoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. 54 61
10712418 2000
13
The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. 61 54
10589700 1999
14
Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. 61 54
10521390 1999
15
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. 61 54
10199872 1999
16
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. 61 54
9796837 1998
17
Coronary thrombosis associated with antithrombin-III deficiency. 61 54
9327319 1997
18
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. 54 61
9012634 1997
19
Identification of active tissue factor in human coronary atheroma. 61 54
8822973 1996
20
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. 54 61
8735626 1996
21
Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. 61 54
8725732 1996
22
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. 61 54
7641354 1995
23
Novel antithrombotic approaches to coronary artery disease. 54 61
7863968 1995
24
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. 61 54
8026028 1994
25
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. 54 61
1451271 1992
26
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction. 61 54
1497553 1992
27
Role of heparin in coronary thrombolysis. 54 61
1555478 1992
28
Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. 54 61
1606285 1992
29
Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig. 61 54
1513078 1992
30
Sudden cardiac death-update. 61
33349905 2021
31
A Review of Coronary Artery Thrombosis: A New Challenging Finding in COVID-19 Patients and ST-elevation Myocardial Infarction. 61
33218787 2021
32
Coronary spasm and optical coherence tomography defined plaque erosion causing ST-segment-elevation acute myocardial infarction in a patient with COVID-19 pneumonia. 61
33052252 2021
33
Coronary Thrombosis and Acute Myocardial Infarction in a Child Following Device Closure of Coronary Artery Fistula. 61
33454294 2021
34
Acute myocardial infarction and large coronary thrombosis in a patient with COVID-19. 61
32767631 2021
35
Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. 61
33220322 2021
36
Diagnosing coronary thrombosis using multiphase post-mortem CT angiography (MPMCTA): A case study. 61
33591864 2021
37
Acute Coronary Artery Thrombosis in a Patient With Non-Small Cell Lung Cancer. 61
33457143 2021
38
Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent. 61
33489138 2021
39
Recurrent coronary thrombotic events in a moderate case of COVID-19. 61
33500300 2021
40
Antithrombotic / Antiplatelet Therapy in Patients with Stable Coronary Artery Disease and after Acute Coronary Syndrome. 61
33290202 2020
41
COVID-19 patient with coronary thrombosis supported with ECMO and Impella 5.0 ventricular assist device: a case report. 61
33442588 2020
42
Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction. 61
33372956 2020
43
Transcatheter Closure of Large Coronary-Cameral Fistulas Using the Patent Ductus Arteriosus Occluder or Amplatzer Vascular Plugs. 61
33191343 2020
44
NIRS-IVUS for Differentiating Coronary Plaque Rupture, Erosion and Calcified Nodule in Acute Myocardial Infarction. 61
33221211 2020
45
Relapse of chronic obstructive pulmonary disease and myocardial infarction: what is the connection? 61
33239991 2020
46
Serious Right Coronary Artery Thrombosis Revealing Behçet's Disease in a Female Patient: A Case Report. 61
33312783 2020
47
Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. 61
33232770 2020
48
Coronary Thrombosis From Superficial Calcific Sheet. 61
32999102 2020
49
Coronary and cerebral thrombosis in a young patient after mild COVID-19 illness: a case report. 61
33200109 2020
50
Ultrasonographic Assessment During Cardiopulmonary Resuscitation. 61
33165330 2020

Variations for Coronary Thrombosis

Expression for Coronary Thrombosis

Search GEO for disease gene expression data for Coronary Thrombosis.

Pathways for Coronary Thrombosis

Pathways related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 VWF SERPINE1 SERPINC1 SELP PLG PLAT
2
Show member pathways
12.64 SERPINE1 PLG ITGB3 ITGA2B FGA
3
Show member pathways
12.23 SERPINE1 PTGS2 PLG PLAT CRP
4
Show member pathways
12.17 VWF ITGB3 ITGA2B FGA
5
Show member pathways
12.04 VWF ITGB3 ITGA2B GP6 GP1BA FGA
6 12.03 VWF SERPINE1 SERPINC1 PLG PLAT FGA
7
Show member pathways
11.97 VWF ITGB3 ITGA2B FGA
8 11.91 SERPINE1 PLG ITGB3 F3
9 11.89 VWF P2RY12 ITGB3 ITGA2B GP6 GP1BA
10 11.85 ITGB3 ITGA2B GP1BA
11
Show member pathways
11.79 VWF ITGB3 ITGA2B GP1BA FGA
12 11.77 ITGB3 ITGA2B GP1BA
13 11.76 VWF PTGS2 ITGB3 F3
14 11.54 SERPINE1 PLG PLAT
15 11.49 SERPINE1 ITGB3 ITGA2B
16
Show member pathways
11.48 VWF SERPINE1 SERPINC1 PLG PLAT GP6
17 11.42 SELP PLG PLAT GP1BA
18 11.41 PLG PLAT FGA
19 11.34 VWF P2RY12 ITGB3 ITGA2B GP6 FGA
20 10.77 VWF GP6 GP1BA
21 10.75 SERPINE1 PLG PLAT
22 10.59 VWF GP1BA

GO Terms for Coronary Thrombosis

Cellular components related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.22 SLC6A4 SERPINE1 SERPINC1 SELP POU2F3 PLG
2 extracellular region GO:0005576 10.11 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT
3 extracellular exosome GO:0070062 10 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT
4 extracellular space GO:0005615 9.9 VWF SERPINF1 SERPINE1 SERPINC1 SELP PLG
5 blood microparticle GO:0072562 9.73 SERPINC1 PLG ITGA2B FGA
6 platelet alpha granule lumen GO:0031093 9.62 VWF SERPINE1 PLG FGA
7 cell surface GO:0009986 9.61 PLG PLAT P2RY12 ITGB3 ITGA2B GP6
8 platelet alpha granule membrane GO:0031092 9.54 SELP ITGB3 ITGA2B
9 platelet alpha granule GO:0031091 9.48 VWF FGA
10 collagen-containing extracellular matrix GO:0062023 9.23 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT

Biological processes related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.97 VWF SELP ITGB3 ITGA2B GP1BA
2 extracellular matrix organization GO:0030198 9.8 VWF SERPINE1 ITGB3 ITGA2B FGA
3 platelet activation GO:0030168 9.8 VWF P2RY12 ITGB3 GP6 GP1BA FGA
4 platelet aggregation GO:0070527 9.77 P2RY12 ITGB3 ITGA2B GP1BA FGA
5 cell-matrix adhesion GO:0007160 9.73 ITGB3 ITGA2B FGA
6 platelet degranulation GO:0002576 9.7 VWF SERPINE1 SELP PLG ITGB3 ITGA2B
7 fibrinolysis GO:0042730 9.65 SERPINE1 PLG PLAT GP1BA FGA
8 cellular response to ATP GO:0071318 9.59 PTGS2 P2RY12
9 vasoconstriction GO:0042310 9.58 SLC6A4 CRP
10 blood coagulation, intrinsic pathway GO:0007597 9.57 VWF GP1BA
11 hemostasis GO:0007599 9.56 VWF SERPINC1 PLG P2RY12 GP6 GP1BA
12 regulation of blood coagulation GO:0030193 9.55 SERPINC1 GP1BA
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.54 ITGB3 CRP
14 positive regulation of leukocyte migration GO:0002687 9.52 SELP ITGA2B
15 plasminogen activation GO:0031639 9.51 PLAT FGA
16 negative regulation of fibrinolysis GO:0051918 9.49 SERPINE1 PLG
17 negative regulation of lipid storage GO:0010888 9.48 ITGB3 CRP
18 smooth muscle cell migration GO:0014909 9.46 PLAT ITGB3
19 negative regulation of synaptic transmission, dopaminergic GO:0032227 9.43 SLC6A4 PTGS2
20 blood coagulation GO:0007596 9.32 VWF SERPINC1 PLG PLAT P2RY12 ITGB3

Molecular functions related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase inhibitor activity GO:0004867 9.33 SERPINF1 SERPINE1 SERPINC1
2 protease binding GO:0002020 9.02 VWF SERPINE1 SERPINC1 ITGB3 F3
3 fibrinogen binding GO:0070051 8.96 ITGB3 ITGA2B

Sources for Coronary Thrombosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....